Posts by Steven Chervenick
Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma (PENINSULA)
In this Phase-II study, the investigators will investigate the efficacy and safety of lenvatinib in combination with pembrolizumab and chemotherapy in patients with malignant pleural mesothelioma.
Read More3D Printing and Optical Scanning Can Improve Mesothelioma Treatment
New treatments and technologies offer hope for mesothelioma patients. One technology, 3D printing and optical scanning, has the potential to help those suffering with mesothelioma. The technologies refine and enhance what is known as photodynamic therapy, a promising new approach for the management of mesothelioma. Photodynamic therapy is a unique treatment that uses light to…
Read MoreExercise to Boost Immunity in Advanced Cancer (BICEP)
The trial is a prospective feasibility trial conducted in Sheffield. Recruitment will include twenty patients receiving first line palliative immunotherapy for advanced, unresectable or metastatic mesothelioma and patients receiving first line systemic anti-cancer treatment for pancreatic cancer. Patients will attend the AWRC for a supervised exercise session once a week to include aerobic exercise along with an unsupervised weekly exercise session for 3 months. Blood samples will be collected at baseline and then monthly for 3 months, pre and post the supervised exercise session. Cytokine, myokine and immune cell concentration will be analysed using cytokine bead-based multiplex immune assays and RNA-seq to full profile changes in gene and protein expression
Read MoreAn Iowa School was Fined for Exposing Workers to Asbestos
An Iowa school district could be fined thousands of dollars for having employees work inside an asbestos-contaminated building. State records were recently released showing that the Iowa Occupational Safety and Health Administration fined the school district $70,000. The school district was also fined another $6,000 by the Iowa Department of Natural Resources. This happened at…
Read MoreNM32-2668 in Adult Patients With Selected Advanced Solid Tumors
This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients with selected advanced solid tumors.
Read MoreImerys Talc America and Cyprus Mines Corporation are Creating a Trust for Asbestos Victims
Imerys Talc America and its former owner, Cyprus Mines Corporation, will create a collective $862 million trust. The reason for the trust is to settle personal injury claims that allege the company’s asbestos contaminated talc caused people’s cancer. This is after both groups filed reorganization plans and disclosure statements on January 31, 2024 in the…
Read MoreTreatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration (PITHAC)
Within the context of pleural carcinosis, the present study is a dose escalation with determination of the maximum tolerated doses (MTD) of pressurized cisplatin administration associated to moderate hyperthermia in the pleura. This will be followed by an expansion phase at the recommended dose (RD).
Read MoreADI-PEG20 Improves Survival in Mesothelioma Patients
ADI-PEG20 is showing promising results for mesothelioma. It is the first treatment to be fully incorporated with chemotherapy in 20 years. The drug will bring hope to thousands of mesothelioma survivors and their families. The drug works by blocking a cancer’s food supply, preventing the spread of the cancer. It does this by absorbing the…
Read MoreAsbestos and Other Carcinogens Were in U.S. Missile Silos
The U.S. Air Force is investigating asbestos and other carcinogens at nuclear missile bases. According to the Associated Press, the use of these carcinogens dates back to the 1980s. There are reports showing that the Air Force knew about the toxic chemicals being used at nuclear launch silos for decades. Documents reveal that there were…
Read MoreGalinpepimut-S Alongside Opdivo Improves Survival in Mesothelioma Patients
Sellas Life Sciences recently reported results from its Phase I clinical trial showing that survival was improved in pleural mesothelioma patients due to its treatment. The trial looked at the treatment called galinpepimut-S (GPS), an immunotherapy vaccine. There were 10 patients in the study with relapsed or refractory mesothelioma. Nine of the patients received at…
Read More